Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press20210.17650/1726-9776-2009-5-1-48-52DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫCLINICAL SIGNIFICANCE OF 5αα-REDUCTASE AND ANDROGEN RECEPTOR GENE POLYMORPHISMS IN PROSTATE CANCERКЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ПОЛИМОРФИЗМОВ ГЕНОВ 5ΑΑ-РЕДУКТАЗЫ И АНДРОГЕНОРЕЦЕПТОРОВ ПРИ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫLoranO. B.ЛоранО. Б.
Russian Federation

Кафедра урологии и хирургической андрологии

LukyanovI. V.ЛукьяновИ. В.
Russian Federation

Кафедра урологии и хирургической андрологии

TuzovD. Yu.ТузовД. Ю.
Russian Federation

Кафедра урологии и хирургической андрологии

TyulpakovA. N.ТюльпаковА. Н.
Russian Federation

Отделение наследственных эндокринопатий и лаборатория молекулярной диагностики 

Department of Urology and Surgical Andrology, Russian Medical Academy of Postgraduate EducationРМАПОDepartment of Hereditary Endocrinopathies and Laboratory of Molecular Diagnosis, Endocrinology Research Center, Russian Agency for Health Care, MoscowЭндокринологическbq научнsq центр Росздрава, Москва300320095148520108201401082014https://oncourology.abvpress.ru/oncur/article/view/202

The development of prostate cancer is inseparably linked with the effect of androgens on the fundamental prostatic intracellular processes,such as proliferation, apoptosis, which is realized through a number of second messengers. Major of them are the AR gene encoding androgenreceptors and the SRD5A2 gene encoding 5α-reductase enzyme. This paper deals with the study of the role of these genes in prostate cancer. 

 

Клиническое значение полиморфизмов генов 5αα-редуктазыи андрогенорецепторов при раке предстательной железы

1. Чиссов В.И., Дарьялова С.Л. Клинические рекомендации. Онкология. ГрифУМО по медицинскому образованию.М.: Гэотар-Медиа, 2006.Чиссов В.И., Дарьялова С.Л. Клинические рекомендации. Онкология. ГрифУМО по медицинскому образованию.М.: Гэотар-Медиа, 2006.2. Сивков А.В., Чернышев И.В., Пере-панова Т.С. и др. Скрининг рака предстательной железы. В кн.: Методические рекомендации. М., 2006.Сивков А.В., Чернышев И.В., Пере-панова Т.С. и др. Скрининг рака предстательной железы. В кн.: Методические рекомендации. М., 2006.3. Edward P.G. Molecular biology of theandrogen receptor. J Clin Oncol2002;20(13):3001—15.Edward P.G. Molecular biology of theandrogen receptor. J Clin Oncol2002;20(13):3001—15.4. Andersson S., Berman D.M., Jenkins E.P.et al. Deletion of steroid 5α-reductase-2gene in male pseudohermaphroditism.Nature 1991;354:159—61.Andersson S., Berman D.M., Jenkins E.P.et al. Deletion of steroid 5α-reductase-2gene in male pseudohermaphroditism.Nature 1991;354:159—61.5. Jenkins E.P., Hsieh C.-L., Milatovich A.et al. Genomics 1991;11:1102—12.Jenkins E.P., Hsieh C.-L., Milatovich A.et al. Genomics 1991;11:1102—12.6. Makridakis N.M., Ross R.K., Pike M.C.Association of mis-sense substitution inSRD5A2 gene with prostate cancer inAfrican-American and Hispanic men in LosAngeles, USA. Lancet 1999;354:975—8.Makridakis N.M., Ross R.K., Pike M.C.Association of mis-sense substitution inSRD5A2 gene with prostate cancer inAfrican-American and Hispanic men in LosAngeles, USA. Lancet 1999;354:975—8.7. Makridakis N.M., di Salle E., Reichardt J.K. Biochemical and pharma-cogenetic dissection of human steroid 5a-reductase type II. Pharmacogenetics2000;10:407—13.Makridakis N.M., di Salle E., Reichardt J.K. Biochemical and pharma-cogenetic dissection of human steroid 5a-reductase type II. Pharmacogenetics2000;10:407—13.8. Tong M., Xu Z., Ai J.K. et al.Assotiation of polymorphism in testosterone5-alpha-reductase II genotype and progno-sis factors of prostate cancer. Zhonghua YiXue Za Zhi 2005;25—85(19):1319—21.Tong M., Xu Z., Ai J.K. et al.Assotiation of polymorphism in testosterone5-alpha-reductase II genotype and progno-sis factors of prostate cancer. Zhonghua YiXue Za Zhi 2005;25—85(19):1319—21.9. Cicek M.S., Conti D.V., Curran A. et al.Association of prostate cancer risk andaggressiveness to androgen pathway genes:SRD5A2, CYP17, and the AR. Prostate2004;59(1):69—76.Cicek M.S., Conti D.V., Curran A. et al.Association of prostate cancer risk andaggressiveness to androgen pathway genes:SRD5A2, CYP17, and the AR. Prostate2004;59(1):69—76.10. Silver R.I., Wiley E.L., Davis D.L.Expression and regulation of steroid 5alpha-reductase 2 in prostate disease. JUrol 1994;152:433—7.Silver R.I., Wiley E.L., Davis D.L.Expression and regulation of steroid 5alpha-reductase 2 in prostate disease. JUrol 1994;152:433—7.11. Thomas L.N., Douglas R.C., Lazier C.B.et al. Type 1 and Type 2 5a-ReductaseExpression in the Development andProgression of Prostate Cancer. Eur Urol2007;52(4):1082—7.Thomas L.N., Douglas R.C., Lazier C.B.et al. Type 1 and Type 2 5a-ReductaseExpression in the Development andProgression of Prostate Cancer. Eur Urol2007;52(4):1082—7.12. Titus M.A., Gregory C.W., Ford 3rd O.H.et al. Steroid 5alphareductase isozymes Iand II in recurrent prostate cancer. ClinCancer Res 2005;11:4365—71.Titus M.A., Gregory C.W., Ford 3rd O.H.et al. Steroid 5alphareductase isozymes Iand II in recurrent prostate cancer. ClinCancer Res 2005;11:4365—71.13. Thomas L.N., Douglas R.C., Vessey J.P.5alpha-reductase type 1 immunostaining isenhanced in some prostate cancers com-pared with benign prostatic hyperplasiaepithelium. J Urol 2003;170:2019—25.Thomas L.N., Douglas R.C., Vessey J.P.5alpha-reductase type 1 immunostaining isenhanced in some prostate cancers com-pared with benign prostatic hyperplasiaepithelium. J Urol 2003;170:2019—25.14. Xu Y., Dalrymple S.L., Becker R.E. et al.Pharmacologic basis for the enhanced effi-cacy of dutasteride against prostatic can-cers. Clin Cancer Res 2006;12:4072—9.Xu Y., Dalrymple S.L., Becker R.E. et al.Pharmacologic basis for the enhanced effi-cacy of dutasteride against prostatic can-cers. Clin Cancer Res 2006;12:4072—9.15. Kousteni S., Bellido T., Plotkin L.I. et al.Nongenotropic, sex-nonspecific signalingthrough the estrogen or androgen recep-tors: dissociation from transcriptionalactivity. Cell 2001;104:719—30.Kousteni S., Bellido T., Plotkin L.I. et al.Nongenotropic, sex-nonspecific signalingthrough the estrogen or androgen recep-tors: dissociation from transcriptionalactivity. Cell 2001;104:719—30.16. Lu S., Tsai S.Y., Tsai M.J. Regulationof androgen-dependent prostatic cancercell growth: androgen regulation of CDK2,CDK4, and CKI p16 genes. Cancer Res1997;57:4111—6.Lu S., Tsai S.Y., Tsai M.J. Regulationof androgen-dependent prostatic cancercell growth: androgen regulation of CDK2,CDK4, and CKI p16 genes. Cancer Res1997;57:4111—6.17. Lee D.K., Chang C. Endocrine mech-anisms of disease: expression and degrada-tion of androgen receptor: mechanism andclinical implication. J Clin EndocrinolMetab 2003;88:4043—54.Lee D.K., Chang C. Endocrine mech-anisms of disease: expression and degrada-tion of androgen receptor: mechanism andclinical implication. J Clin EndocrinolMetab 2003;88:4043—54.18. Ross R.K., Pike M.C., Coetzee G.A.Androgen metabolism and prostate cancer:establishing a model of genetic susceptibili-ty. Cancer Res 1998;58:4497—504.Ross R.K., Pike M.C., Coetzee G.A.Androgen metabolism and prostate cancer:establishing a model of genetic susceptibili-ty. Cancer Res 1998;58:4497—504.19. Feldman D. Androgen and vitamin Dreceptor gene polymorphisms: the long andshort of prostate cancer risk. J Natl CancerInst 1997;85:1571—9.Feldman D. Androgen and vitamin Dreceptor gene polymorphisms: the long andshort of prostate cancer risk. J Natl CancerInst 1997;85:1571—9.20. La Spada A.R., Wilson E.M., Lubahn D.B. et al Androgen receptor genemutations in X-linked spinal and bulbarmuscular atrophy. Nature 1991;352:77—9.La Spada A.R., Wilson E.M., Lubahn D.B. et al Androgen receptor genemutations in X-linked spinal and bulbarmuscular atrophy. Nature 1991;352:77—9.21. George D. et al. The role androgenreceptor and prostate cancer. Clin CancerRes 2003;11:3273—9.George D. et al. The role androgenreceptor and prostate cancer. Clin CancerRes 2003;11:3273—9.22. Hsing A.W., Gao Y.T., Wu G. et al.Polymorphic CAG and GGN repeat lengthsin the androgen receptor and prostate cancerrisk: a population-based case control study inChina. Cancer Res 2000;60:5111—6.Hsing A.W., Gao Y.T., Wu G. et al.Polymorphic CAG and GGN repeat lengthsin the androgen receptor and prostate cancerrisk: a population-based case control study inChina. Cancer Res 2000;60:5111—6.23. Edwards S.M., Badzioch M.D., Minter R. et al. Androgen receptor poly-morphisms: association with prostate can-cer risk, relapse, and overall survival. Int JCancer 1999;84:458—65.Edwards S.M., Badzioch M.D., Minter R. et al. Androgen receptor poly-morphisms: association with prostate can-cer risk, relapse, and overall survival. Int JCancer 1999;84:458—65.